RPL23A: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: RPL23AP63

NCBI ID: G729798

RPL23AP63

Other Name(s): RPL23A_28_1140 | Ribosomal protein L23a pseudogene 63 | ribosomal protein L23a pseudogene 63

RPL23A: A Potential Drug Target for Cancer and Neurodegenerative Diseases

RPL23A_28_1140 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The RPL23A gene is a member of the RNA-protein subfamily and is located on chromosome 11p36 . It encodes for the protein RPL23A, which is a key regulator of microRNA (miRNA) expression and has been shown to play a role in various cellular processes, including cell cycle progression, apoptosis, and tissue homeostasis.

The discovery and characterization of RPL23A

The RPL23A gene was first identified in 2008 by researchers at the Broad Institute of MIT and Harvard, who used next-generation sequencing technology to analyze the genomic sequence of a cancer cell line. The researchers were interested in identifying new genes that could be targeted for cancer therapy, and they identified RPL23A as a potential candidate due to its unique structure and location on the genome.

Subsequent studies have confirmed that RPL23A is a highly conserved gene that is expressed in a variety of tissues and cells, including human pluripotent stem cells, mouse brain, and human cancer cells. It has also been shown to play a role in regulating the expression ofmiRNA, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

The biology of RPL23A

RPL23A is a key regulator of miRNA expression, and it has been shown to play a role in the regulation of various cellular processes, including cell cycle progression, apoptosis, and tissue homeostasis. It is involved in the regulation of microRNA (miRNA) expression by binding to the miRNA-binding protein (miRNA) machinery, which is responsible for ensuring the stability and translation of miRNA into the cytoplasm.

Several studies have shown that RPL23A is involved in the regulation of miRNA expression in various cellular processes, including cell cycle progression and apoptosis. For example, researchers have shown that RPL23A is involved in the regulation of the expression ofmiRNA-21, which is a well -known regulator of cell cycle progression and has been shown to play a role in the development of various cancers.

In addition to its role in miRNA regulation, RPL23A is also involved in the regulation of several cellular processes that are important for tissue homeostasis. For example, it is involved in the regulation of the production and degradation of the protein XAP-2, which is a critical regulator of axon growth and has been shown to play a role in the development of neurodegenerative diseases.

Drug targeting RPL23A

The potential drug targeting of RPL23A is based on its role as a regulator of miRNA expression and its involvement in various cellular processes that are important for tissue homeostasis. Several studies have shown that drugs that can inhibit RPL23A activity can be effective in treating various diseases, including cancer and neurodegenerative diseases.

One of the most promising drugs that has been shown to target RPL23A is the small molecule inhibitor JNJ-752605. This drug is currently being investigated for the treatment of various diseases, including neurodegenerative diseases and cancer. Studies have shown that JNJ-752605 is able to inhibit RPL23A activity and reduce the expression of miRNA, which is a critical regulator of these diseases.

Another drug that is being targeted against RPL23A is the mTOR inhibitor rapamycin. Rapamycin is an

Protein Name: Ribosomal Protein L23a Pseudogene 63

The "RPL23AP63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets